Home » Puma Starts Phase II Clinical Trial of Tumor Drug
Puma Starts Phase II Clinical Trial of Tumor Drug
Puma Biotechnology has started a Phase II trial of neratinib, a cancer drug targeting patients with solid tumors with HER-2 mutations.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May